期刊文献+

帕瑞昔布钠主要降解杂质-伐地昔布的HPLC测定方法研究 被引量:5

Study on the determinationthe major degradation impurities-valdecoxib in parecoxib sodium by HPLC method
原文传递
导出
摘要 目的建立高效液相色谱法测定帕瑞昔布钠的主要降解杂质及工艺杂质。方法采用Phenomenex C18(150 mm×4.6 mm,5μm)色谱柱,以乙腈-0.01 mol/L磷酸氢二钠溶液(pH=3.0)(40∶60,V/V)为流动相,检测波长为215 nm,流速1.0 ml/min。结果帕瑞昔布钠及其主要降解杂质伐地昔布在0.5μg/ml^5.0μg/ml范围内,浓度与响应值峰面积的线性关系良好,相关系数分别为r=0.9997和r=0.9992。平均加标回收率为100.2%±3.3%(n=9)。结论本方法准确度、精密度、灵敏度等均较好,可用于帕瑞昔布钠主要降解杂质的测定,能有效控制帕瑞昔布的质量。 Objective A RP- HPLC method was established for the determination of the major degradation impurities and process impurities in Parecoxib sodium. Methods The separation was performed on a Phenomenex C18column( 150 mm ×4. 6 mm,5 μm). The mobile phase was acetonitrile- disodium hydrogen phosphate buffer solution( 0. 01 mol /L)( pH3. 0)( 40∶60,V/V). The detection was carried out with a uv detector at 215 nm. The flow rate was 1.0 ml/min. Results The linear relationship between its major degradation impurities valdecoxib with the concentration of 0. 5 μg /ml - 5. 0 μg /ml and the response values of peak area was good,and the correlation coefficients were r = 0. 9997 and r = 0. 9992,respectively. The average recovery was 100. 2% ± 3. 3%( n = 9). Conclusion The method was proved to be accurate,sensitive and reliable,which can be used for determination of the major degradation impurities- valdecoxib in Parecoxib sodium. The method is used to effectively control the quality of parecoxib.
作者 许瑞 张建杰
出处 《中国卫生检验杂志》 北大核心 2014年第19期2785-2786,2790,共3页 Chinese Journal of Health Laboratory Technology
关键词 帕瑞昔布钠 伐地昔布 高效液相色谱 Parecoxib sodium Valdecoxib HPLC
  • 相关文献

参考文献5

二级参考文献62

  • 1吴新民,岳云,张利萍,王俊科,艾登滨,于布为,薛张纲,黄文起.术后镇痛中帕瑞昔布钠对吗啡用量的节俭作用和安全性—前瞻性、多中心、随机、双盲、安慰剂对照、平行分组研究[J].中华麻醉学杂志,2007,27(1):7-10. 被引量:367
  • 2Koboldt M, Talley JJ, Seibert K, et al. N- [ [ (5-Methyl-3- phenylisoxazol-4-yl) penyl] sulfonyl] propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration [J]. J Med Chem, 2000, 43 (5) : 775-777.
  • 3Letendre L J, Kunda SA, Gallagher DJ, et al. Method for preparing valdecoxib and related benzenesulfonyl compounds: WO, 2003029230 [P]. 2003-04-10. (CA 2003, 138: 304268).
  • 4Letendre L J, Snoddy CK, Klemm George H, et al. Method for the preparation of diarylisoxazole sulfonamide compounds and intermediates: WO, 2005123701 [P]. 2005-12-29. (CA 2005, 144: 88274).
  • 5Di NL, Vitale P, Scilimati A, et al. Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib:reversal cyclooxygenase-2selectivity by sulfonamide group removal [J]. J Med Chem, 2004, 47 (20) : 4881-4890.
  • 6Sundaram V, Bhimireddy A, Eswaraiah S, et al. A method for preparing 3,4-diphenylsubstituted isoxazole derivatives such as valdecoxib, parecoxib, and their intermediates: EP,1550658 [P].2005-07-06.
  • 7Thakashinamoorthy C, Jesudoss MG, Hariharasubramania M, et al. A novel process for preparing valdecoxib: WO, 2005085218 [P. 2005-09-15. (CA2005, 145: 124547).
  • 8乇凯,陈长谭,易安茂.一种制备帕瑞昔布的方法:中国,102329277[P].2012-01-25.
  • 9Reddy AR, Goverdhan G, Sampath A, et al. Application of [3+2]-cycloaddition in the synthesis of valdecoxib [J]. Synth Commun, 2012, 42 (5) : 639-649.
  • 10Kumar JS Dileep, Ho MM, Leung JM, et al. Convenient approach to 3,4-diarylisoxazoles based on the Suzuki cross- coupling reaction [J]. Advanced Synth Cat, 2002, 344 (10) : 1146-1151.

共引文献145

同被引文献37

引证文献5

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部